BioSpace News Archive

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced the presentation of positive retrospective case study data supporting DEXYCU® 9% for the treatment of post-operative inflammation following ocular surgery.

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that the Phase 1 study of ALX148 in patients with relapsed/refractory Non-Hodgkin Lymphoma has been selected for an e-Poster presentation at the Virtual 25th Annual Congress of EHA, June 11 – 14, 2020.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced additional findings from its Phase II study of Namodenoson in the treatment of patients with non-alcoholic fatty liver disease with or without non-alcoholic steatohepatitis.

AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® has been granted Breakthrough Therapy Designation in the US for the treatment of patients with metastatic non-small cell lung cancer whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.

bluebird bio, Inc. announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the shares of common stock offered in the public offering.

After two doses all participants evaluated to date across the 25 µg and 100 µg dose cohorts seroconverted with binding antibody levels at or above levels seen in convalescent sera mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants across the 25 µg and 100 µg dose cohorts, reaching or exceeding neutralizing antibody titers generally seen in convalescent sera mRNA-1273 was generally safe and well tolerated

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will participate in a fireside chat at the SunTrust Robinson Humphrey Virtual Meeting Series, hosted by analyst, Sandy Draper. The fireside chat will take place on Friday, May 2

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring pre-clinical data on CUE-102/A02 and CUE-102/A24, the company’s second and third drug candidates from the CUE-100 series at the American Association for Cancer Research (AACR) Virtual Annual Meeti

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that Christian S. Schade, President and Chief Executive Officer, and Eyal C. Attar, Senior Vice President and Chief Medical Officer, will participate in a fireside discussion at the 2020 RBC Capital Markets Global Healthcare Conference on Wednesday,